- Home
- OGEN vs NEUP Comparison
OGEN vs NEUP Comparison
Compare OGEN & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- NEUP
- Stock Information
- Founded
- OGEN 1996
- NEUP 1996
- Country
- OGEN United States
- NEUP United States
- Employees
- OGEN N/A
- NEUP N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- OGEN Health Care
- NEUP
- Exchange
- OGEN Nasdaq
- NEUP Nasdaq
- Market Cap
- OGEN 5.5M
- NEUP 17.4B
- IPO Year
- OGEN N/A
- NEUP N/A
- Fundamental
- Price
- OGEN $0.28
- NEUP $5.09
- Analyst Decision
- OGEN
- NEUP Strong Buy
- Analyst Count
- OGEN 0
- NEUP 1
- Target Price
- OGEN N/A
- NEUP $21.00
- AVG Volume (30 Days)
- OGEN 507.3K
- NEUP 1.4M
- Earning Date
- OGEN 03-28-2025
- NEUP 02-13-2025
- Dividend Yield
- OGEN N/A
- NEUP N/A
- EPS Growth
- OGEN N/A
- NEUP N/A
- EPS
- OGEN N/A
- NEUP N/A
- Revenue
- OGEN N/A
- NEUP N/A
- Revenue This Year
- OGEN N/A
- NEUP N/A
- Revenue Next Year
- OGEN N/A
- NEUP N/A
- P/E Ratio
- OGEN N/A
- NEUP N/A
- Revenue Growth
- OGEN N/A
- NEUP N/A
- 52 Week Low
- OGEN $0.25
- NEUP $2.12
- 52 Week High
- OGEN $4.00
- NEUP $16.08
- Technical
- Relative Strength Index (RSI)
- OGEN 41.56
- NEUP N/A
- Support Level
- OGEN $0.34
- NEUP N/A
- Resistance Level
- OGEN $0.32
- NEUP N/A
- Average True Range (ATR)
- OGEN 0.03
- NEUP 0.00
- MACD
- OGEN 0.00
- NEUP 0.00
- Stochastic Oscillator
- OGEN 41.80
- NEUP 0.00
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.